Cyclerion Therapeutics Inc

Cyclerion Therapeutics Inc

CYCN - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$318.12M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Cyclerion Therapeutics IncCyclerion Therapeutics Inc-0.1--13%--
$0.58

Current Fair Value

97.5% downside

Overvalued by 97.5% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$318.12 Million
Enterprise Value$-136,827,653.00
Earnings per Share$-7.63
Beta1.75
Outstanding Shares13,525,610

Return

Return on Equity-13.32%ROE
Return on Assets-11.29%
Return on Invested Capital-12.94%

Valuation & Multiples

P/E Ratio-0.09P/E Ratio
PEG0PEG
Price to Sales-Price to Sales
Price to Book Ratio0.78Price to Book Ratio
Enterprise Value to Revenue-299.3
Enterprise Value to EBIT5.67
Enterprise Value to Net Income2
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 11, 2026
EPS Estimate
-$50.40
Consensus analyst estimate
Revenue Estimate
$550,000
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %1982.38%▲ 1439.23%
Total Invested$390.07M▲ 3388.73%
Investors Holding23▲ 2.00%

About Cyclerion Therapeutics Inc

1 employees
CEO: Jonathan Violin

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules ...

Cyclerion Therapeutics Insider Information FAQ

In the latest 13F quarter on Stockcircle, 3 top investors reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.